Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol

Archives of Gynecology and Obstetrics

Volumn 291, Issue 5, 2015, Pages 1181-1186

  Laganà, Antonio Simone ^a   Barbaro, Luisa ^b   Pizzo, Alfonsa ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b ASP N5   (Italy)

Author keywords

D Chiro Inositol; Metabolic factors; Ovarian function; Polycystic Ovary Syndrome

Indexed keywords

ANDROSTENEDIONE; DEXTRO CHIRO INOSITOL; FOLIC ACID; FOLLITROPIN; GLUCOSE; INOSITOL DERIVATIVE; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; INOSITOL; VITAMIN B COMPLEX;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; METABOLISM; OUTCOME ASSESSMENT; OVARIAN FUNCTION TEST; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; BLOOD; DRUG EFFECTS; EVALUATION STUDY; MENSTRUATION DISTURBANCES; METRORRHAGIA; MIDDLE AGED; OLIGOMENORRHEA; OVARY; PATHOPHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; FEMALE; FOLIC ACID; FOLLICLE STIMULATING HORMONE; HUMANS; INOSITOL; LUTEINIZING HORMONE; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; METRORRHAGIA; MIDDLE AGED; OLIGOMENORRHEA; OVARY; POLYCYSTIC OVARY SYNDROME; PROLACTIN; PROSPECTIVE STUDIES; TESTOSTERONE; TREATMENT OUTCOME; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 84925534174     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-014-3552-6     Document Type: Article

References (56)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749
3. Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685–697
4. Franks S, Adams J, Mason H, Polson D (1985) Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 12:605–632
5. Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169
6. Nestler JE, Jakubowicz DJ (1996) Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617–623
7. Nestler JE, Jakubowicz DJ (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82:4075–4079
8. Franks S (1989) Polycystic ovary syndrome. A changing perspective. Clin Endocrinol (Oxf) 31:87–120
9. James RG, Krakower GR, Kissebah AH (1996) Influence of androgenicity on adipocytes and precursor cells in female rats. Obes Res 4:463–470
10. Schuring AN, Schulte N, Sonntag B, Kiesel L (2008) Androgens and insulin–two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch 48:9–15
11. Buckler HM, McLachlan RI, MacLachlan VB, Healy DL, Burger HG (1988) Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration. J Clin Endocrinol Metab 66:798–803
12. Franks S, Sagle M, Mason HD, Kiddy D (1987) Use of LHRH agonists in the treatment of anovulation in women with polycystic ovary syndrome. Horm Res 28:164–168
13. Burghen GA, Givens JR, Kitabchi AE (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50:113–116
14. Azziz R (2003) Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 80:252–254
15. Baillargeon JP, Carpentier A (2007) Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 88:886–893
16. Baptiste CG, Battista MC, Trottier A, Baillargeon JP (2010) Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 122:42–52
17. González F, Rote NS, Minium J, Kirwan JP (2006) Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91:336–340
18. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K (1999) Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 71:323–327
19. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G (1999) Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340:1314–1320
20. Gerli S, Mignosa M, Di Renzo GC (2003) Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 7:151–159
21. Ng EH, Wat NM, Ho PC (2001) Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 16:1625–1631
22. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE (2002) Effects of d-chiroinositol in lean women with the polycystic ovary syndrome. Endocr Pract 8:417–423
23. Larner J (1994) Multiple pathways in insulin signaling—fitting the covalent and allosteric puzzle pieces together. Endocr J 2:167–171
24. Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M (2014) The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 54:1079–1092
25. Larner J (2002) d-chiro-inositol–its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 3:47–60
26. Unfer V, Porcaro G (2014) Updates on the myo-inositol plus d-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol 7:623–631
27. Genazzani AD, Santagni S, Ricchieri F, Campedelli A, Rattighieri E, Chierchia E, Marini G, Despini G, Prati A, Simoncini T (2014) Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. J Obstet Gynaecol Res 40:1353–1360
28. Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V (2013) Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 29:375–379
29. Venturella R, Mocciaro R, De Trana E, D’Alessandro P, Morelli M, Zullo F (2012) Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol. Minerva Ginecol 64:239–243
30. Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG (2012) Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 28:969–973
31. Unfer V, Carlomagno G, Dante G, Facchinetti F (2012) Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 28:509–515
32. Brusco GF, Mariani M (2013) Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci 17:3095–3102
33. Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD (2014) Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol 26:1–5
34. Colazingari S, Treglia M, Najjar R, Bevilacqua A (2013) The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 288:1405–1411
35. Lisi F, Carfagna P, Oliva MM, Rago R, Lisi R, Poverini R, Manna C, Vaquero E, Caserta D, Raparelli V, Marci R, Moscarini M (2012) Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 10:52
36. D’Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, Corrado F, Di Benedetto A (2013) myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 36:854–857
37. Matarrelli B, Vitacolonna E, D’Angelo M, Pavone G, Mattei PA, Liberati M, Celentano C (2013) Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med 26:967–972
38. D’Anna R, Di Benedetto V, Rizzo P, Raffone E, Interdonato ML, Corrado F, Di Benedetto A (2012) Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 28:440–442
39. Corrado F, D’Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A (2011) The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med 28:972–975
40. Pizzo A, Laganà AS, Barbaro L (2014) Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol 30:205–208
41. Grimes DA, Schulz KF (2002) Cohort studies: marching towards outcomes. Lancet 359:341–345
42. Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials 11:32
43. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trial. BMJ 340:c869
44. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D (2013) SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 346:e7586
45. Swanson M, Sauerbrei EE, Cooperberg PL (1981) Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 9:219–222
46. La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A (2014) The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 30:1–5
47. Di Paolo G, De Camilli P (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443:651–657
48. Chen IW, Charalampous CF (1966) Biochemical studies on inositol. IX. d-Inositol 1-phosphate as intermediate in the biosynthesis of inositol from glucose 6-phosphate, and characteristics of two reactions in this biosynthesis. J Biol Chem 241:2194–2199
49. Isabella R, Raffone E (2012) Does ovary need d-chiro-inositol? J Ovarian Res 5:14
50. Huang LC, Fonteles MC, Houston DB, Zhang C, Larner J (1993) Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology 132:652–657
51. Ortmeyer HK, Bodkin NL, Lilley K, Larner J, Hansen BC (1993) Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology 132:640–645
52. Asplin I, Galasko G, Larner J (1993) Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myoinositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 90:5924–5928
53. Ortmeyer HK, Huang LC, Zhang L, Hansen BC, Larner J (1993) Chiroinositol deficiency and insulin resistance. II. Acute effects of d-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin resistant rhesus monkeys. Endocrinology 132:646–651
54. Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, Prati A, Simoncini T (2014) Modulatory role of d-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 30:438–443
55. Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE (2004) Metformin therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:242–249
56. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE (2006) Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 29:300–305